Cipla is up in the green today morning as the market is happy with its recent purchase of an anti-diabetic trademark and brand.

The company has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis. The company made no mention of the financial details of the acquisition.

The company, as such has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin).

The market size of Vildagliptin in India is Rs 818 crore as per IQVIA MAT data of November 2019.